BiQ: Quick Note About Merck's Phase 3 CORALreef AddOn Results for Enlicitide Decanoate 03/30/26

This morning, Merck posted a PR highlighting recent results from its Phase 3 CORALreef AddOn trial for Enlicitide Decanoate (ED), comparing efficacy and safety to Bempedoic Acid (BA), Ezetimibe, and BA+Ezetimibe:

https://www.merck.com/news/mercks-enlicitide-decanoate-an-investigational-oral-pcsk9-inhibitor-demonstrated-significantly-greater-ldl-c-reductions-at-eight-weeks-compared-to-guideline-recommended-oral-non-statin-ther/

There is little doubt in my mind that ED is a great drug, and once approved, will be a strong option for patients needing deep reduction in LDL-C. In addition to allowing for daily oral dosing and a clean safety profile, ED demonstrated very strong efficacy versus BA, as well as other PCSK9s, such as Repatha and Leqvio. I think ED will be a strong competitor in the PCSK9 market, and once approved, will be well positioned to potentially take market share from its PCSK9 competitors.

However, in this article, I'm more interested in exploring how its potential (and very likely) approval might affect the growth trajectory of Bempedoic Acid and Bempedoic Acid + Ezitimibe, currently marketed as Nexletol and Nexlizet in the US.